Beida Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
300558SZSE
Announcement on the Change of Continuous Supervision Sponsor Representative for the 2020 Private Placement of Shares
✨ AI Summary
This announcement details the change of the continuous supervision sponsor representative for the 2020 private placement of shares by Beida Pharmaceutical. Due to a work transfer, Mr. Xu Feng will be replaced by Mr. Yu Qidong. The continuous supervision period will last until the obligations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange are fulfilled. The change will not affect the company's operations or supervision.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.